11/10/2023
MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), has...
03/10/2023
We are a Life Science Venture Capital with a passion for investing in drug development, both because it is extremely exciting but also because we contribute to moving new therapies closer to patients with severe, untreated diseases – we matter! – we make a tangible...
We use cookies on the website sunstone.eu in order to generate statistics and to maximize user-friendliness and improve functionality. By using our website, you consent to our use of cookies. Click on cookie settings below if you wish to disable cookies. Or you can read more about what cookies are, how we use them and how you disable cookies Here.
Cookie settingsAccept Privacy & Cookies Policy
Recent Comments